Bristol-Myers Squibb Compnay

Bristol Meyers Squibb Company

Syngene International Limited

Ling Chen

Guanglin Luo

John E Macor

Gene Michael Dubowchik

Prasad V Chaturvedula

Graham S Poindexter

George O Tora

Andrew P Degnan

Chunjian Liu

Stephen T Wrobleski

Michael G Yang

Joanne J Bronson

David S Weinstein

John S Tokarski

Prasanna Sivaprakasam

Carolyn Diane Dzierba

Zili Xiao

Ryan M Moslin

Xiaojun Han

Rita Civiello

Jonathan L Ditta

Swanee E Jacutin-Porte

Xiang Jun J Jiang

Ramesh Kumar Sistla

Susheel Jethanand Nara

Ramkumar Rajamani

Prasada Rao Jalagam

Soodamani Thangavel

Tarun Kumar Maishal

George N Karageorge

Richard A Hartz

Vivekananda M Vrudhula

Vijay T Ahuja

Senliang Pan

Shikha Vig

Charles Mark Conway

Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R, R, R, R, and Rare as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

Sulfone pyridine alkyl amide-substituted heteroaryl compounds

Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R, R, R, R, and Rare as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN&#x3b1;, by acting on Tyk-2 to cause signal transduction inhibition.

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3. 

GSK-3 inhibitors

The present disclosure relates to compounds of formula I which inhibit NaV1.7, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions. 

Acyl sulfonamide NaV1.7 inhibitors

The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia. 

Biaryl kinase inhibitors

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system. 

Substituted pyridine derivatives useful as GSK-3 inhibitors

The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD). 

CGRP receptor antagonists

The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors ('CGRP-receptor'), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

Anti-migraine spirocycles

Heterocyclic anti-migraine agents

The present invention relates to methods of treating neurogenic vasodilation, neurogenic inflammaton, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors using pharmaceutical compositions comprising compounds of Formula (I) 

Anti-migraine treatments

Calcitonin gene related peptide receptor antagonists

Growing community of inventors

Middletown, CT, United States of America

Ling Chen